Johnson & Johnson reports ICOTYDE data. Johnson & Johnson stock trades at EUR 227.50 vs EUR 227.45
Published on 10/03/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson reported new ICOTYDE data on October 2, 2026, according to its press release. Johnson & Johnson stock was at EUR 227.50 in weekend trading at Lang & Schwarz at 10:06 a.m. CEST on October 3, 2026, up 0.02 percent versus the EUR 227.45 close at Lang & Schwarz on October 2, 2026.
Weekend trading
Lang & Schwarz quoted the stock at EUR 227.50, compared with a bid of EUR 227.25 and an ask of EUR 227.75. The EUR 227.50 price was EUR 0.05 above the EUR 227.45 close at Lang & Schwarz on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Last Xetra trading day
The last Xetra trading day ended with a EUR 227.45 close at Lang & Schwarz on October 2, 2026. Xetra remains closed during the weekend trading session, with the next Xetra session scheduled for October 5, 2026.
ICOTYDE psoriasis data
Johnson & Johnson said two-year results from the Phase 3 ICONIC-TOTAL study showed sustained skin clearance through Week 112. The company reported that 60 percent of patients with scalp psoriasis and 89 percent of patients with genital psoriasis achieved site-specific complete skin clearance at Week 112. Among patients treated with ICOTYDE, clear or almost clear skin increased from 57 percent at Week 16 to 70 percent at Week 112, according to the Johnson & Johnson release. The findings were presented at the European Academy of Dermatology and Venereology Congress 2026.
